AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30064491
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg then 40 mg 2 weeks later)
Trial: 25952495
Drug: Medication-taking consistency
RxNorm normalized name: Fusion protein consisting of il-15n72d and il-15rasu/fc
DrugBank: Nogapendekin alfa (DB18740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-taking consistency
Trial: 14614165
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CTLA4Ig per kilogram
Trial: 14614165
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg CTLA4Ig per kilogram
Trial: 11374857
Drug: Immediate-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release niacin
Trial: 11374857
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (Niaspan)
Trial: 1385567
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg intravenous doses, two doses: one before anesthesia induction and one 8 hours later)
Trial: 1385567
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two doses of placebo vehicle: one before anesthesia induction and one 8 hours later)
Trial: 31591063
Drug: Ramucirumab plus
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab plus erlotinib (150 mg/day erlotinib, 10 mg/kg ramucirumab every 2 weeks)
Trial: 31591063
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus erlotinib (150 mg/day erlotinib)
Trial: 21451504
Drug: PF‐4878691 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐4878691 (3, 6, and 9 mg doses, twice a week for 2 weeks)
Trial: 21451504
Drug: PF‐4878691 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐4878691 (9 mg dose)
Trial: 19653753
Drug: Body-related objects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body-related objects (e.g., cup) with movement toward the subject's body
Trial: 19653753
Drug: World-related objects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: World-related objects (e.g., pincers) with movement in the opposite direction
Trial: 16965983
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (enoxaparin, 4000 IU/d, n = 56 hypertensive patients)
Trial: 16965983
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 38 hypertensive women)
Trial: 14976884
Drug: Modified Zhizhu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Zhizhu pill (ZZP) 100 ml, twice daily, orally taken half an hour before meal
Trial: 14976884
Drug: Ranitidine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 0.15 g, twice daily and Cisapride 10 mg, three times a day, orally taken before meal
Trial: 9382344
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (Group 2)
Trial: 27118284
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group 3)
Trial: 8407393
Drug: IUdR 96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IUdR 96 hr infusion schedule
Trial: 8407393
Drug: IUdR 48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IUdR 48 hr infusion schedule
Trial: 8407393
Drug: IUdR 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IUdR 24 hr infusion schedule
Trial: 22092641
Drug: Moraxella bovis
RxNorm normalized name: Moraxella catarrhalis subsp. catarrhalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moraxella bovis autogenous vaccine
Trial: 8290859
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg daily for 28 days)
Trial: 20444662
Drug: glimepiride+metformin
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride+metformin
Trial: 18721198
Drug: Single gram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single gram of intramuscular ceftriaxone
Trial: 18721198
Drug: 3-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day course of oral ciprofloxacin
Trial: 18721198
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 500 mg of ciprofloxacin
Trial: 17013573
Drug: TAX/RT (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAX/RT (paclitaxel 90 mg/m² or docetaxel 35 mg/m²)
Trial: 17013573
Drug: TAX/CIS/RT (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAX/CIS/RT (paclitaxel 135 mg/m² d1 and cisplatin 20 mg/m² d1-5 q28)
Trial: 15226460
Drug: NCEP Step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NCEP Step 2 high‐fish diet (n = 11, 26% of energy as fat, 4.5% as saturated fat, and 15 mg cholesterol/MJ)
Trial: 15226460
Drug: NCEP Step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NCEP Step 2 low‐fish diet (n = 11, 26% of energy as fat, 4.0% as saturated fat, and 11 mg cholesterol/MJ)
Trial: 14685384
Drug: High-fat oral
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat oral supplement (Group I)
Trial: 14685384
Drug: Standard diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diet without supplement (Control Group II)
Trial: 8457050
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml 2% lidocaine, followed by 10 ml every 45 min (Control)
Trial: 8457050
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of 3% chloroprocaine (containing EDTA), plus 5 ml every 45 min
Trial: 8457050
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 3% chloroprocaine plus 10 ml every 45 min
Trial: 8457050
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 3% chloroprocaine (containing metabisulfite as the preservative but no EDTA) plus 10 ml every 45 min
Trial: 8457050
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 3% chloroprocaine with the pH adjusted to 7.3, plus 10 ml every 45 min
Trial: 3836297
Drug: Labetalol (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100, 200, 400, 600 mg BID)
Trial: 3836297
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 or 50 mg BID)
Trial: 12847531
Drug: 2-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day antibiotic therapy (AT)
Trial: 12847531
Drug: 4-day antibiotic
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day antibiotic therapy (AT)
Trial: 10584976
Drug: Intravenous Zofran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Zofran
Trial: 8884403
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy with mothers present
Trial: 8884403
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy without mothers present
Trial: 31007170
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel (5 mL applied topically to the cervix 5 minutes prior to paracervical blockade)
Trial: 29318656
Drug: Finasteride (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (an androgen bioactivation inhibitor)
Trial: 26961599
Drug: Meals supplemented
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meals supplemented with 1.4 g of cocoa extract (645 mg polyphenols)
Trial: 24743880
Drug: Post-febrile malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-febrile malaria treatment
Trial: 22992045
Drug: Influenza A
RxNorm normalized name: influenza A virus
DrugBank: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) (DB14444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A H1N1/2009 vaccine
Trial: 11978262
Drug: Oat cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat cereal group (5.52 g/day beta-glucan)
Trial: 11978262
Drug: Low-fiber cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber cereal control group (less than 1.0 g/day total fiber)
Trial: 8534671
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg daily simvastatin, 20 mg daily simvastatin, Matching placebo
Trial: 389264
Drug: Ibuprofen (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1600 mg daily) and soluble aspirin (3.6 g daily)
Trial: 389264
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg daily) and soluble aspirin (2.4 g daily)
Trial: 389264
Drug: Ibuprofen (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (single drug period)
Trial: 389264
Drug: Salicylate (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylate (single drug period)
Trial: 389264
Drug: Concurrent salicylate
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent salicylate administration
Trial: 28605609
Drug: VPRO (CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPRO (CHO 75 g, protein 25 g, vitamins D3 5000 IU, K2 1000 μg)
Trial: 28605609
Drug: PRO (CHO
RxNorm normalized name: Vital E- Repro (cholecalciferol 100000 UNT/ML / vitamin A 200000 UNT/ML / vitamin E 300 UNT/ML) Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO (CHO 75 g, protein 25 g, no vitamins)
Trial: 22143664
Drug: Digital radiographs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital radiographs with full dose
Trial: 22143664
Drug: Digital radiographs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital radiographs with reduced dose
Trial: 19553594
Drug: Active migraine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active migraine with frequency < monthly
Trial: 19553594
Drug: Active migraine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active migraine with frequency monthly
Trial: 19553594
Drug: Active migraine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active migraine with frequency >or= weekly
Trial: 19553594
Drug: Active migraine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active migraine with aura and frequency < monthly
Trial: 19553594
Drug: Active migraine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active migraine with aura and frequency >or= weekly
Trial: 3058919
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulfate (20 mg elemental zinc twice daily)
Trial: 3058919
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulfate (20 mg elemental zinc twice daily) in subjects with severe initial zinc depletion
Trial: 28429377
Drug: Olfactory training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory training (OT) group, daily olfactory exposure for 5 months
Trial: 28429377
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, daily Sudoku problems for 5 months
Trial: 27923410
Drug: Brazil nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil nuts (approximately 48 µg/d as six Brazil nuts)
Trial: 27923410
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) capsules (four GTE capsules, 800 mg (‐)‐epigallocatechin‐3‐gallate)
Trial: 27923410
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Brazil nuts and GTE
Trial: 25339632
Drug: Integrated management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated management (daily contact with monitoring centre using handheld PDA)
Trial: 23525414
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 81 mg daily
Trial: 18334143
Drug: Hirudin-treated group
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin-treated group (peroral administration of Maixuekang capsules)
Trial: 18334143
Drug: Dipyridamole-treated group
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole-treated group (peroral administration of dipyridamole)
Trial: 12911866
Drug: 60% honey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% honey solution inhalation
Trial: 12911866
Drug: Distill water
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distill water inhalation
Trial: 12911866
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose inhalation
Trial: 11313239
Drug: Peripheral blood
RxNorm normalized name: Peripheral blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood stem cell (PBSC) donors treated with 5 to 7 days of filgrastim at a dose of 16 microg/kg/d and underwent 1 to 3 days of apheresis to obtain 5 x 10(6) CD34(+) cells per kilogram recipient weight.
Trial: 8195519
Drug: Spinal cord
RxNorm normalized name: BOS TAURUS SPINAL CORD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal cord stimulation (treatment group)
Trial: 3298383
Drug: L-Cystine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Cystine and Pyridoxine Hydrochloride combination (in addition to classical post-operative treatment)
Trial: 3298383
Drug: Classical post-operative
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical post-operative treatment (control group)
Trial: 28133772
Drug: FKB327 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKB327 (40 mg)
Trial: 28133772
Drug: EU-Humira (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-Humira (40 mg)
Trial: 28133772
Drug: US-Humira (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-Humira (40 mg)
Trial: 25870124
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B (Red yeast rice (Monakolin K 3.3 mg), Berberine 531.25 mg and leaf extract of Morus alba)
Trial: 25870124
Drug: Combination A
RxNorm normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination A (Policosanol, Red yeast rice (Monakolin K 3 mg), Berberine 500 mg, Astaxantine, Folic Acid and Coenzyme Q10)
Trial: 25870124
Drug: Combination A
RxNorm normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination A and Combination B
Trial: 25870124
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B
Trial: 21248446
Drug: Cetuximab with
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab with oral sorafenib
Trial: 19064532
Drug: Cocoa treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa treatment (150 mL twice a day, approximately 900 mg flavanols/d)
Trial: 19064532
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (approximately 28 mg flavanols/d)
Trial: 15767642
Drug: Combination (Anastrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (Anastrozole + Tamoxifen)
Trial: 10864051
Drug: Dexamethasone at
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone at a dose of 6 mg/m2 per day (standard risk) or 18 mg/m2 per day (high risk)
Trial: 10864051
Drug: Prednisone at
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone at a dose of 40 mg/m2/d (standard risk) or 120 mg/m2/d (high risk)
Trial: 29481452
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg·kg)
Trial: 24793028
Drug: Mesalamine dose
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine dose escalation (2.4 g/day increase for 6 weeks)
Trial: 24793028
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued current dose of mesalamine)
Trial: 24793028
Drug: Mesalamine dose
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine dose escalation
Trial: 24793028
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with FC >200 μg/g
Trial: 11524326
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block with 1.5% mepivacaine (40 mL) followed by a postoperative intraarticular infusion of 0.5% ropivacaine at 2 mL/h
Trial: 11524326
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block with 0.5% ropivacaine (40 mL) followed by a postoperative intraarticular infusion of 0.9% saline (placebo) at 2 mL/h
Trial: 8237931
Drug: iv metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv metoclopramide (20‐mg bolus)
Trial: 20518170
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (Ximen (PC 4), Yinxi (HT 6), Xuehai (SP 10), Zhaohai (KI 6)) for 10 days
Trial: 20518170
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Carbamazepine) for 10 days
Trial: 12742991
Drug: Troglitazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (600 mg/day for 12 weeks)
Trial: 9085015
Drug: Dexniguldipine (DNIG)
DrugBank: Dexniguldipine (DB14068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexniguldipine (DNIG) 1-11 mg/kg/4h infusion
Trial: 9085015
Drug: Vinblastine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine 0.15 mg/kg
Trial: 9085015
Drug: Long-term infusion
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term infusion of DNIG (5 and 7 mg/kg/24h)
Trial: 9085015
Drug: DNIG infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNIG infusion (5 and 7 mg/kg/4h)
Trial: 9085015
Drug: DNIG infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNIG infusion
Trial: 10920613
Drug: Mycobacterium w
RxNorm normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium w vaccine
Trial: 29490024
Drug: Granulocyte/Monocyte Apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte/Monocyte Apheresis (GMA) plus oral prednisone (40 mg/day and tapering)
Trial: 11043499
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone alone
Trial: 29490024
Drug: Granulocyte/Monocyte Apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte/Monocyte Apheresis (GMA) plus oral prednisone (GMA group)
Trial: 16405522
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy based on BNP levels
Trial: 16405522
Drug: BNP cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP cut-off level of 1.25 pmol L(‐1)
Trial: 7680832
Drug: Synthetic porcine
RxNorm normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic porcine galanin (0.5 mg in 100 ml saline)
Trial: 7680832
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (100 ml saline)
Trial: 3554804
Drug: Bencyclane 200
RxNorm normalized name: bencyclane 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencyclane 200 mg b.i.d.
Trial: 29708822
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg TID for 2 weeks (open-label treatment)
Trial: 29708822
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg TID for 2 weeks (double-blind treatment)
Trial: 29708822
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 2 weeks (double-blind treatment)